| Doptelet (avatrombopag) / SOBI |
NCT01433978 / 2011-000831-10: A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura) |
|
|
| Terminated | 3 | 24 | US | Eltrombopag, Promacta, Revolade, Avatrombopag, E5501, Avatrombopag maleate, Standard of care | Eisai Inc. | Idiopathic Thrombocytopenic Purpura | 09/13 | 09/13 | | |
NCT01438840 / 2011-000830-12: Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02) |
|
|
| Completed | 3 | 49 | Europe, RoW | Avatrombopag, E5501, Avatrombopag maleate, Placebo, Standard of care | Eisai Inc. | Chronic Thrombocytopenia, Immune Thrombocytopenia | 11/13 | 03/14 | | |
| Completed | 3 | 231 | US, Canada, Europe, RoW | avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count) | Eisai Inc. | Thrombocytopenia Associated With Liver Disease | 01/17 | 02/17 | | |
| Completed | 3 | 204 | Japan, US, Canada, Europe, RoW | avatrombopag (lower baseline platelet count), placebo (lower baseline platelet count), avatrombopag (higher baseline platelet count), placebo (higher baseline platelet count) | Eisai Inc. | Thrombocytopenia Associated With Liver Disease | 01/17 | 02/17 | | |
NCT03326843: Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure |
|
|
| Terminated | 3 | 4 | US | Avatrombopag 60 mg | Sobi, Inc. | Thrombocytopenia | 02/19 | 02/19 | | |
NCT03471078 / 2018-000023-13: Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers |
|
|
| Completed | 3 | 122 | Europe, US, RoW | Avatrombopag, Placebo Oral Tablet | Sobi, Inc. | Chemotherapy-induced Thrombocytopenia | 08/20 | 01/23 | | |
| Active, not recruiting | 3 | 75 | Europe, US, RoW | Avatrombopag, Doptelet, Placebo | Sobi, Inc. | Immune Thrombocytopenia | 11/23 | 11/25 | | |
NCT05369208: Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults with Chronic ITP |
|
|
| Active, not recruiting | 3 | 19 | Japan | Avatrombopag Oral Tablet, Doptelet | Sobi, Inc. | Immune Thrombocytopenia | 01/24 | 08/25 | | |
NCT05046327: Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months |
|
|
| Withdrawn | 3 | 0 | NA | Avatrombopag 20 mg Oral Tablet, Doptelet | Dova Pharmaceuticals | Immune Thrombocytopenia | 04/24 | 02/25 | | |
NCT05907499: Decitabine for Poor Graft Function Post Allo-HSCT |
|
|
| Not yet recruiting | 3 | 76 | NA | Decitabine, Dec, Granulocyte Colony-Stimulating Factor, G-CSF, Thrombopoietin Receptor Agonist, Eltrombopag / Avatrombopag, Recombinant human erythropoietin, EPO | The First Affiliated Hospital of Soochow University | Poor Graft Function | 07/26 | 11/26 | | |
| Not yet recruiting | 2/3 | 40 | RoW | Avatrombopag 20 MG | Peking Union Medical College Hospital | Aplastic Anemia, Drug Effect | 12/22 | 06/23 | | |
| Not yet recruiting | 2/3 | 142 | RoW | avatrombopag, Doptelet, Placebo | Peking University People's Hospital, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital, First Affiliated Hospital of Harbin Medical University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital of Xinjiang Medical University, Shanxi Bethune Hospital, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Tang-Du Hospital, The First Affiliated Hospital of Nanchang University | Thrombocytopenia, Stem Cell Transplant Complications | 10/24 | 10/25 | | |
